Kane Biotech Expands U.S. Distribution Of revyve® Wound Care Line, New Agreements With Patient Care Medical And Life Biologics Broaden Market Reach

Kane Biotech Inc. has entered into non-exclusive distribution and sales agreements for its revyve® Antimicrobial Wound Gel® product line with Patient Care Medical and Life Biologics. The agreements are designed to strengthen Kane Biotech’s commercial footprint in the United States by expanding access across targeted sales channels and geographic regions.

Life Biologics will distribute the revyve® product line nationally within the advanced wound care market, while Patient Care Medical will focus on Louisiana, Mississippi, and the Gulf Coast region, serving hospitals and mobile wound care facilities. The company has indicated that preparations are currently underway for initial product shipments.

“Expanding our U.S. distribution network remains a key priority for the Company,” said Dr Robert Huizinga, Interim CEO of Kane Biotech. “These agreements enhance our access to selected U.S. markets and support our near-term commercialisation objectives.”

Kane Biotech specialises in developing wound care solutions that target biofilms, which are a significant contributor to antibiotic resistance and poor healing outcomes. The revyve® portfolio, including Antimicrobial Wound Gel, Wound Gel Spray, and Skin and Wound Cleanser, is cleared by the U.S. Food and Drug Administration under the 510(k) pathway. Additionally, the Wound Gel and Wound Gel Spray products have received Health Canada approval.